WO2022166845A1 - 一种纤溶酶抑制剂、其制备方法及应用 - Google Patents
一种纤溶酶抑制剂、其制备方法及应用 Download PDFInfo
- Publication number
- WO2022166845A1 WO2022166845A1 PCT/CN2022/074754 CN2022074754W WO2022166845A1 WO 2022166845 A1 WO2022166845 A1 WO 2022166845A1 CN 2022074754 W CN2022074754 W CN 2022074754W WO 2022166845 A1 WO2022166845 A1 WO 2022166845A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- naphthyridine
- tert
- hydrogen
- reaction
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 129
- 229940122791 Plasmin inhibitor Drugs 0.000 title description 2
- 239000002806 plasmin inhibitor Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 153
- 239000000203 mixture Substances 0.000 claims abstract description 55
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 239000000651 prodrug Substances 0.000 claims abstract description 23
- 229940002612 prodrug Drugs 0.000 claims abstract description 23
- 230000023597 hemostasis Effects 0.000 claims abstract description 3
- -1 amino, phenyl Chemical group 0.000 claims description 66
- 229910052739 hydrogen Inorganic materials 0.000 claims description 39
- 239000001257 hydrogen Substances 0.000 claims description 39
- 150000002431 hydrogen Chemical class 0.000 claims description 31
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 30
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 19
- 150000004677 hydrates Chemical class 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 13
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 208000032843 Hemorrhage Diseases 0.000 claims description 10
- 125000002723 alicyclic group Chemical group 0.000 claims description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
- 208000034158 bleeding Diseases 0.000 claims description 10
- 230000000740 bleeding effect Effects 0.000 claims description 10
- 239000000460 chlorine Substances 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 125000003368 amide group Chemical group 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 230000015271 coagulation Effects 0.000 claims description 8
- 238000005345 coagulation Methods 0.000 claims description 8
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000002757 morpholinyl group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 125000006848 alicyclic heterocyclic group Chemical group 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000006618 5- to 10-membered aromatic heterocyclic group Chemical group 0.000 claims description 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 206010051077 Post procedural haemorrhage Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 108010088842 Fibrinolysin Proteins 0.000 abstract description 4
- 229940012957 plasmin Drugs 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000023555 blood coagulation Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 162
- 238000006243 chemical reaction Methods 0.000 description 158
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 104
- 238000000132 electrospray ionisation Methods 0.000 description 104
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 90
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 69
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 62
- 239000000243 solution Substances 0.000 description 57
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 51
- 239000012043 crude product Substances 0.000 description 50
- 230000002829 reductive effect Effects 0.000 description 49
- 239000012074 organic phase Substances 0.000 description 45
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 41
- 238000004440 column chromatography Methods 0.000 description 35
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 32
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 29
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 19
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 18
- 238000005481 NMR spectroscopy Methods 0.000 description 18
- 229910002091 carbon monoxide Inorganic materials 0.000 description 18
- 230000002439 hemostatic effect Effects 0.000 description 17
- 238000004128 high performance liquid chromatography Methods 0.000 description 17
- 229910052757 nitrogen Inorganic materials 0.000 description 17
- 229940086542 triethylamine Drugs 0.000 description 17
- 238000000746 purification Methods 0.000 description 14
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 14
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- 239000012141 concentrate Substances 0.000 description 12
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 12
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 10
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 9
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 9
- 229960000401 tranexamic acid Drugs 0.000 description 9
- 102000013566 Plasminogen Human genes 0.000 description 8
- 108010051456 Plasminogen Proteins 0.000 description 8
- 239000012298 atmosphere Substances 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- QZBVGNKIDZMRSU-UHFFFAOYSA-N tert-butyl 2-chloro-8-methylsulfonyloxy-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate Chemical compound CC(C)(C)OC(N(CC1OS(C)(=O)=O)CC(C=C2)=C1N=C2Cl)=O QZBVGNKIDZMRSU-UHFFFAOYSA-N 0.000 description 8
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 7
- 102000009123 Fibrin Human genes 0.000 description 7
- 108010073385 Fibrin Proteins 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 229950003499 fibrin Drugs 0.000 description 7
- 125000006413 ring segment Chemical group 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- LPZHKCVGWZFNDC-UHFFFAOYSA-N tert-butyl 2-chloro-7,8-dihydro-5h-1,6-naphthyridine-6-carboxylate Chemical compound ClC1=CC=C2CN(C(=O)OC(C)(C)C)CCC2=N1 LPZHKCVGWZFNDC-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- NRRADXDSPCCCRF-UHFFFAOYSA-N tert-butyl 2-chloro-7-formyl-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate Chemical compound CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1Cl)C2C=O)=O NRRADXDSPCCCRF-UHFFFAOYSA-N 0.000 description 5
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 229960002684 aminocaproic acid Drugs 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- XCKHXCJKOTXWSX-UHFFFAOYSA-N tert-butyl 2-chloro-1-oxido-7,8-dihydro-5h-1,6-naphthyridin-1-ium-6-carboxylate Chemical compound C1=CC(Cl)=[N+]([O-])C2=C1CN(C(=O)OC(C)(C)C)CC2 XCKHXCJKOTXWSX-UHFFFAOYSA-N 0.000 description 4
- MIHZWUHBJFMDNM-UHFFFAOYSA-N tert-butyl 2-chloro-8-hydroxy-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate Chemical compound CC(C)(C)OC(N(CC1O)CC(C=C2)=C1N=C2Cl)=O MIHZWUHBJFMDNM-UHFFFAOYSA-N 0.000 description 4
- FRACHJCOMOVESL-UHFFFAOYSA-N 2-chloro-5,6,7,8-tetrahydro-1,6-naphthyridine;hydrochloride Chemical compound Cl.C1NCCC2=NC(Cl)=CC=C21 FRACHJCOMOVESL-UHFFFAOYSA-N 0.000 description 3
- SUCDJGXNPUSISJ-UHFFFAOYSA-N 2-chloro-6-[(2-methylpropan-2-yl)oxycarbonyl]-7,8-dihydro-5H-1,6-naphthyridine-7-carboxylic acid Chemical compound CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1Cl)C2C(O)=O)=O SUCDJGXNPUSISJ-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241000282567 Macaca fascicularis Species 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 239000003527 fibrinolytic agent Substances 0.000 description 3
- 230000003480 fibrinolytic effect Effects 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- CCBOIKKKPTZDBS-UHFFFAOYSA-N 2-chloro-3-fluoro-5,6,7,8-tetrahydro-1,6-naphthyridine Chemical compound C1NCCC2=C1C=C(F)C(Cl)=N2 CCBOIKKKPTZDBS-UHFFFAOYSA-N 0.000 description 2
- SHWYVHBDJKHOHW-UHFFFAOYSA-N 2-chloro-5-fluoro-6-[(4-methoxyphenyl)methoxy]pyridine-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1COC1=NC(Cl)=C(C#N)C=C1F SHWYVHBDJKHOHW-UHFFFAOYSA-N 0.000 description 2
- QDJCTHJSORGMMT-UHFFFAOYSA-N 2-ethenyl-5-fluoro-6-[(4-methoxyphenyl)methoxy]pyridine-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1COC1=NC(C=C)=C(C#N)C=C1F QDJCTHJSORGMMT-UHFFFAOYSA-N 0.000 description 2
- NEDGJWKNIJJCAL-UHFFFAOYSA-N 2-methyl-n-pentan-3-ylidenepropane-2-sulfinamide Chemical compound CCC(CC)=NS(=O)C(C)(C)C NEDGJWKNIJJCAL-UHFFFAOYSA-N 0.000 description 2
- UIZITQMNQQTAEL-UHFFFAOYSA-N 3,4-dihydropyridine-2,6-dicarboxylic acid Chemical compound OC(=O)C1=NC(C(O)=O)=CCC1 UIZITQMNQQTAEL-UHFFFAOYSA-N 0.000 description 2
- YZJOXKHVQXQQDT-UHFFFAOYSA-M 3-[tert-butyl(dimethyl)silyl]oxypropyl-triphenylphosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCO[Si](C)(C)C(C)(C)C)C1=CC=CC=C1 YZJOXKHVQXQQDT-UHFFFAOYSA-M 0.000 description 2
- DJSJSODKAYFLQU-UHFFFAOYSA-N 5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylic acid;hydrochloride Chemical compound Cl.C1NCCC2=NC(C(=O)O)=CC=C21 DJSJSODKAYFLQU-UHFFFAOYSA-N 0.000 description 2
- QPANLAKDVQHLRJ-UHFFFAOYSA-N 6-benzyl-2-chloro-3-fluoro-7,8-dihydro-5H-1,6-naphthyridine Chemical compound C(C1=CC=CC=C1)N1CC=2C=C(C(=NC=2CC1)Cl)F QPANLAKDVQHLRJ-UHFFFAOYSA-N 0.000 description 2
- WOFWUSNZPFBSPY-UHFFFAOYSA-N 6-benzyl-3-fluoro-2-[(4-methoxyphenyl)methoxy]-7,8-dihydro-1,6-naphthyridin-5-one Chemical compound C(C1=CC=CC=C1)N1C(C=2C=C(C(=NC=2CC1)OCC1=CC=C(C=C1)OC)F)=O WOFWUSNZPFBSPY-UHFFFAOYSA-N 0.000 description 2
- ZJSWKVAPSCIRIE-UHFFFAOYSA-N 6-benzyl-3-fluoro-2-[(4-methoxyphenyl)methoxy]-7,8-dihydro-5H-1,6-naphthyridine Chemical compound COC1=CC=C(COC2=C(F)C=C3CN(CC4=CC=CC=C4)CCC3=N2)C=C1 ZJSWKVAPSCIRIE-UHFFFAOYSA-N 0.000 description 2
- XQMVICDINIHBII-UHFFFAOYSA-N 6-chloro-2,3-bis(chloromethyl)pyridine Chemical compound ClCC1=CC=C(Cl)N=C1CCl XQMVICDINIHBII-UHFFFAOYSA-N 0.000 description 2
- WSSBHZAVMOMREB-UHFFFAOYSA-N 7,7-diethyl-1,5,6,8-tetrahydro-1,6-naphthyridin-2-one Chemical compound CCC(CC)(C1)NCC(C=C2)=C1N=C2O WSSBHZAVMOMREB-UHFFFAOYSA-N 0.000 description 2
- UHEUHYOWCNJUEJ-UHFFFAOYSA-N 7,7-diethyl-2-methoxy-6,8-dihydro-1,6-naphthyridin-5-one Chemical compound CCC(CC)(CC1=C2C=CC(OC)=N1)NC2=O UHEUHYOWCNJUEJ-UHFFFAOYSA-N 0.000 description 2
- NWNHAGHKVJPHSN-UHFFFAOYSA-N 7,7-diethyl-2-methoxy-6,8-dihydro-5H-1,6-naphthyridine Chemical compound CCC(CC)(C1)NCC(C=C2)=C1N=C2OC NWNHAGHKVJPHSN-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- XGTCVHYOFIDJJE-UHFFFAOYSA-N CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1C(O)=O)C2C(N)=O)=O Chemical compound CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1C(O)=O)C2C(N)=O)=O XGTCVHYOFIDJJE-UHFFFAOYSA-N 0.000 description 2
- HHUIHEYJJFCJKP-UHFFFAOYSA-N CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1C(O)=O)C2C(O)=O)=O Chemical compound CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1C(O)=O)C2C(O)=O)=O HHUIHEYJJFCJKP-UHFFFAOYSA-N 0.000 description 2
- GRPJRYBHPBRZSS-UHFFFAOYSA-N CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1C(OC)=O)C2C(OC)=O)=O Chemical compound CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1C(OC)=O)C2C(OC)=O)=O GRPJRYBHPBRZSS-UHFFFAOYSA-N 0.000 description 2
- KMALUFNCKWDCFN-UHFFFAOYSA-N CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1Cl)C2C(C1=CC=CC=C1)O)=O Chemical compound CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1Cl)C2C(C1=CC=CC=C1)O)=O KMALUFNCKWDCFN-UHFFFAOYSA-N 0.000 description 2
- MCOKKMDZLIGTPS-UHFFFAOYSA-N CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1Cl)C2C1(CC1)O)=O Chemical compound CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1Cl)C2C1(CC1)O)=O MCOKKMDZLIGTPS-UHFFFAOYSA-N 0.000 description 2
- PJZSDEUUNGAAEU-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CC2=C1N=C(C(O)=O)C(F)=C2)=O Chemical compound CC(C)(C)OC(N(CC1)CC2=C1N=C(C(O)=O)C(F)=C2)=O PJZSDEUUNGAAEU-UHFFFAOYSA-N 0.000 description 2
- GENGWYXDXXUXIW-UHFFFAOYSA-N CC(C)(C)OC(N(CC1N(CC2)CCS2(=O)=O)CC(C=C2)=C1N=C2C#N)=O Chemical compound CC(C)(C)OC(N(CC1N(CC2)CCS2(=O)=O)CC(C=C2)=C1N=C2C#N)=O GENGWYXDXXUXIW-UHFFFAOYSA-N 0.000 description 2
- MFUHVTPDOWNNJB-UHFFFAOYSA-N CC(C)(C)OC(N(CC1N(CC2)CCS2(=O)=O)CC(C=C2)=C1N=C2Cl)=O Chemical compound CC(C)(C)OC(N(CC1N(CC2)CCS2(=O)=O)CC(C=C2)=C1N=C2Cl)=O MFUHVTPDOWNNJB-UHFFFAOYSA-N 0.000 description 2
- MTWJBGLHRMHGGY-UHFFFAOYSA-N CC(C)(C)OC(N(CC1N2CC(CC3=CC=CC=C3)OCC2)CC(C=C2)=C1N=C2C#N)=O Chemical compound CC(C)(C)OC(N(CC1N2CC(CC3=CC=CC=C3)OCC2)CC(C=C2)=C1N=C2C#N)=O MTWJBGLHRMHGGY-UHFFFAOYSA-N 0.000 description 2
- CELBGNGSYCAANJ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1N2CC(CC3=CC=CC=C3)OCC2)CC(C=C2)=C1N=C2Cl)=O Chemical compound CC(C)(C)OC(N(CC1N2CC(CC3=CC=CC=C3)OCC2)CC(C=C2)=C1N=C2Cl)=O CELBGNGSYCAANJ-UHFFFAOYSA-N 0.000 description 2
- IVABZUYCCLPNHL-UHFFFAOYSA-N CC(C)(C)OC(N(CC1N=[N+]=[N-])CC(C=C2)=C1N=C2Cl)=O Chemical compound CC(C)(C)OC(N(CC1N=[N+]=[N-])CC(C=C2)=C1N=C2Cl)=O IVABZUYCCLPNHL-UHFFFAOYSA-N 0.000 description 2
- UTOMRMRVLOXTHY-UHFFFAOYSA-N CC(C)(C)OC(N(CC1NCCO)CC(C=C2)=C1N=C2Cl)=O Chemical compound CC(C)(C)OC(N(CC1NCCO)CC(C=C2)=C1N=C2Cl)=O UTOMRMRVLOXTHY-UHFFFAOYSA-N 0.000 description 2
- DFOMZSYSQIDJCL-UHFFFAOYSA-N CC(C)(C)OC(N(CC1O)CC(C=C2)=C1N=C2C(OC)=N)=O Chemical compound CC(C)(C)OC(N(CC1O)CC(C=C2)=C1N=C2C(OC)=N)=O DFOMZSYSQIDJCL-UHFFFAOYSA-N 0.000 description 2
- BAEXYZDNYLRIRS-UHFFFAOYSA-N CC(C)(C)OC(N(CCO)C(CN(C1)C(OC(C)(C)C)=O)C2=C1C=CC(Cl)=N2)=O Chemical compound CC(C)(C)OC(N(CCO)C(CN(C1)C(OC(C)(C)C)=O)C2=C1C=CC(Cl)=N2)=O BAEXYZDNYLRIRS-UHFFFAOYSA-N 0.000 description 2
- YCYYJWUNBABBJH-UHFFFAOYSA-N CC(C)(C)OC(NC(CN(C1)C(OC(C)(C)C)=O)C2=C1C=CC(C#N)=N2)=O Chemical compound CC(C)(C)OC(NC(CN(C1)C(OC(C)(C)C)=O)C2=C1C=CC(C#N)=N2)=O YCYYJWUNBABBJH-UHFFFAOYSA-N 0.000 description 2
- KUAGAIPWGMYWQT-UHFFFAOYSA-N CC(C)(C)OC(NC(CN(C1)C(OC(C)(C)C)=O)C2=C1C=CC(Cl)=N2)=O Chemical compound CC(C)(C)OC(NC(CN(C1)C(OC(C)(C)C)=O)C2=C1C=CC(Cl)=N2)=O KUAGAIPWGMYWQT-UHFFFAOYSA-N 0.000 description 2
- LRHZTUOIUGGIPP-UHFFFAOYSA-N COC(C1=NC(CC(C(C2=CC=CC=C2)O)NC2)=C2C=C1)=O Chemical compound COC(C1=NC(CC(C(C2=CC=CC=C2)O)NC2)=C2C=C1)=O LRHZTUOIUGGIPP-UHFFFAOYSA-N 0.000 description 2
- UFKKBVALWHAYGW-UHFFFAOYSA-N COC(C1=NC(CC(C(CCCO)O)NC2)=C2C=C1)=O Chemical compound COC(C1=NC(CC(C(CCCO)O)NC2)=C2C=C1)=O UFKKBVALWHAYGW-UHFFFAOYSA-N 0.000 description 2
- KNZUYGTVBPZKRB-UHFFFAOYSA-N COC(C1=NC(CC(CNCCCO)NC2)=C2C=C1)=O Chemical compound COC(C1=NC(CC(CNCCCO)NC2)=C2C=C1)=O KNZUYGTVBPZKRB-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- AJDZDIDNTFJJBJ-UHFFFAOYSA-N N-[3-[(3-bromo-6-methoxypyridin-2-yl)methyl]pentan-3-yl]-2-methylpropane-2-sulfinamide Chemical compound CCC(CC)(CC1=NC(OC)=CC=C1Br)NS(C(C)(C)C)=O AJDZDIDNTFJJBJ-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- AURNCCDRERCCJY-UHFFFAOYSA-N [6-chloro-2-(hydroxymethyl)pyridin-3-yl]methanol Chemical compound OCC1=CC=C(Cl)N=C1CO AURNCCDRERCCJY-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- XEVROCIBWHZFQS-UHFFFAOYSA-N dimethyl 1-oxidopyridin-1-ium-2,3-dicarboxylate Chemical compound COC(=O)C1=CC=C[N+]([O-])=C1C(=O)OC XEVROCIBWHZFQS-UHFFFAOYSA-N 0.000 description 2
- KEKUTUAIDOVRDG-UHFFFAOYSA-N dimethyl 6-chloropyridine-2,3-dicarboxylate Chemical compound COC(=O)C1=CC=C(Cl)N=C1C(=O)OC KEKUTUAIDOVRDG-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- NXMCBCQSWXBYJH-UHFFFAOYSA-N ethyl 2-[2-(tert-butylsulfinylamino)-2-ethylbutyl]-6-methoxypyridine-3-carboxylate Chemical compound CCC(CC)(CC(N=C(C=C1)OC)=C1C(OCC)=O)NS(C(C)(C)C)=O NXMCBCQSWXBYJH-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- XCRBXWCUXJNEFX-UHFFFAOYSA-N peroxybenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- XZAIZHURLABPEI-UHFFFAOYSA-N tert-butyl 2-chloro-3-fluoro-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate Chemical compound ClC1=NC=2CCN(CC=2C=C1F)C(=O)OC(C)(C)C XZAIZHURLABPEI-UHFFFAOYSA-N 0.000 description 2
- SHFYEZSZFUAPAP-UHFFFAOYSA-N tert-butyl 2-chloro-7,7-diethyl-5,8-dihydro-1,6-naphthyridine-6-carboxylate Chemical compound CCC(CC)(CC1=C(C2)C=CC(Cl)=N1)N2C(OC(C)(C)C)=O SHFYEZSZFUAPAP-UHFFFAOYSA-N 0.000 description 2
- LMVPVIZIJOYDDY-UHFFFAOYSA-N tert-butyl 2-chloro-7-[methoxy(methyl)carbamoyl]-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate Chemical compound CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1Cl)C2C(N(C)OC)=O)=O LMVPVIZIJOYDDY-UHFFFAOYSA-N 0.000 description 2
- NBOFGABSFFWWFX-UHFFFAOYSA-N tert-butyl 2-chloro-8-morpholin-4-yl-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate Chemical compound CC(C)(C)OC(N(CC(C1=N2)N3CCOCC3)CC1=CC=C2Cl)=O NBOFGABSFFWWFX-UHFFFAOYSA-N 0.000 description 2
- FYOTYCXSXHSVHN-UHFFFAOYSA-N tert-butyl 2-cyano-7,8-dihydro-5h-1,6-naphthyridine-6-carboxylate Chemical compound N#CC1=CC=C2CN(C(=O)OC(C)(C)C)CCC2=N1 FYOTYCXSXHSVHN-UHFFFAOYSA-N 0.000 description 2
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 150000004684 trihydrates Chemical class 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- BLMUWDUSOSTGMM-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,6-naphthyridine-2-carboxylic acid Chemical compound OC(=O)C1CCc2cnccc2N1 BLMUWDUSOSTGMM-UHFFFAOYSA-N 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- DEDKKOOGYIMMBC-UHFFFAOYSA-N 2,6-dichloro-5-fluoropyridine-3-carbonitrile Chemical compound FC1=CC(C#N)=C(Cl)N=C1Cl DEDKKOOGYIMMBC-UHFFFAOYSA-N 0.000 description 1
- XHYVBIXKORFHFM-UHFFFAOYSA-N 2-amino-6-methylbenzoic acid Chemical compound CC1=CC=CC(N)=C1C(O)=O XHYVBIXKORFHFM-UHFFFAOYSA-N 0.000 description 1
- YZFCMGWCEXUGFX-UHFFFAOYSA-N 2-benzylmorpholine Chemical compound C=1C=CC=CC=1CC1CNCCO1 YZFCMGWCEXUGFX-UHFFFAOYSA-N 0.000 description 1
- SBJIXKYQHCIGHH-UHFFFAOYSA-N 2-chloro-7,7-diethyl-6,8-dihydro-5H-1,6-naphthyridine Chemical compound CCC(CC)(C1)NCC(C=C2)=C1N=C2Cl SBJIXKYQHCIGHH-UHFFFAOYSA-N 0.000 description 1
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- XPFNRRRGXGJZNX-UHFFFAOYSA-N 2-piperidin-4-yl-5-pyridin-3-yl-1,3,4-oxadiazole Chemical compound C1CNCCC1C1=NN=C(C=2C=NC=CC=2)O1 XPFNRRRGXGJZNX-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- VWNXCCTWVAQAPL-UHFFFAOYSA-N 3-bromo-6-methoxy-2-methylpyridine Chemical compound COC1=CC=C(Br)C(C)=N1 VWNXCCTWVAQAPL-UHFFFAOYSA-N 0.000 description 1
- QGMROEZDWJTIDW-UHFFFAOYSA-N 3-bromopropoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCCBr QGMROEZDWJTIDW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- LWWKJQCUXKHZAR-UHFFFAOYSA-N CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1C(OC)=O)C2C(N)=O)=O Chemical compound CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1C(OC)=O)C2C(N)=O)=O LWWKJQCUXKHZAR-UHFFFAOYSA-N 0.000 description 1
- DJSVUUBBSYAYGI-UHFFFAOYSA-N CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1C(OC)=O)C2C1(CC1)O)=O Chemical compound CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1C(OC)=O)C2C1(CC1)O)=O DJSVUUBBSYAYGI-UHFFFAOYSA-N 0.000 description 1
- GBKDTEUSSKYEJR-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CC2=C1N=C(C(OC)=O)C(F)=C2)=O Chemical compound CC(C)(C)OC(N(CC1)CC2=C1N=C(C(OC)=O)C(F)=C2)=O GBKDTEUSSKYEJR-UHFFFAOYSA-N 0.000 description 1
- BNFNSPKMWURPJT-UHFFFAOYSA-N CC(C)(C)[Si](C)(C)OCCCOCC(C1)N=CC(C=C2)=C1N=C2Cl Chemical compound CC(C)(C)[Si](C)(C)OCCCOCC(C1)N=CC(C=C2)=C1N=C2Cl BNFNSPKMWURPJT-UHFFFAOYSA-N 0.000 description 1
- OLZOKMBMSJTTIW-UHFFFAOYSA-N CC(N(CC(C=C1)=C(C2)N=C1Cl)C2(C(O)=O)C(O)=O)=O Chemical compound CC(N(CC(C=C1)=C(C2)N=C1Cl)C2(C(O)=O)C(O)=O)=O OLZOKMBMSJTTIW-UHFFFAOYSA-N 0.000 description 1
- RKLGBVVUGJAKBD-UHFFFAOYSA-N CCC(CC)(CC1=C(C2)C=CC(C(O)=O)=N1)N2C(OC(C)(C)C)=O Chemical compound CCC(CC)(CC1=C(C2)C=CC(C(O)=O)=N1)N2C(OC(C)(C)C)=O RKLGBVVUGJAKBD-UHFFFAOYSA-N 0.000 description 1
- HMIDHXWXRPOLLM-UHFFFAOYSA-N CCC(CC)(CC1=C(C2)C=CC(C(OCC)=O)=N1)N2C(OC(C)(C)C)=O Chemical compound CCC(CC)(CC1=C(C2)C=CC(C(OCC)=O)=N1)N2C(OC(C)(C)C)=O HMIDHXWXRPOLLM-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VZEXJUAYWWLSEP-UHFFFAOYSA-N N.[Cl].Cl Chemical compound N.[Cl].Cl VZEXJUAYWWLSEP-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PNIYIDFMZBYHNE-UHFFFAOYSA-N OC(C1=NC(C=CN(C2)C(O)=O)=C2C=C1)=O Chemical compound OC(C1=NC(C=CN(C2)C(O)=O)=C2C=C1)=O PNIYIDFMZBYHNE-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- LQOKJTGPSRWHCM-UHFFFAOYSA-M [Br-].CC(C)(C)[Si](C)(C)OCCC[Mg+] Chemical compound [Br-].CC(C)(C)[Si](C)(C)OCCC[Mg+] LQOKJTGPSRWHCM-UHFFFAOYSA-M 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- MNZMECMQTYGSOI-UHFFFAOYSA-N acetic acid;hydron;bromide Chemical compound Br.CC(O)=O MNZMECMQTYGSOI-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- JTXJZBMXQMTSQN-UHFFFAOYSA-N amino hydrogen carbonate Chemical compound NOC(O)=O JTXJZBMXQMTSQN-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000504 antifibrinolytic agent Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 229940078916 carbamide peroxide Drugs 0.000 description 1
- QJFKYVFGMFPPKM-UHFFFAOYSA-N carbonic acid;4-methylcyclohexan-1-amine Chemical compound OC(O)=O.CC1CCC(N)CC1 QJFKYVFGMFPPKM-UHFFFAOYSA-N 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UKNZIQFPZSCIPW-UHFFFAOYSA-N dicyclohexyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane methanesulfonic acid Chemical group CS(O)(=O)=O.CC(C)c1cc(C(C)C)c(c(c1)C(C)C)-c1ccccc1P(C1CCCCC1)C1CCCCC1 UKNZIQFPZSCIPW-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- IAFSRAPRRFNEFH-UHFFFAOYSA-N dimethyl 6-acetyl-2-chloro-5,8-dihydro-1,6-naphthyridine-7,7-dicarboxylate Chemical compound CC(N(CC(C=C1)=C(C2)N=C1Cl)C2(C(OC)=O)C(OC)=O)=O IAFSRAPRRFNEFH-UHFFFAOYSA-N 0.000 description 1
- YLGIBCYHQZTFQL-UHFFFAOYSA-N dimethyl pyridine-2,3-dicarboxylate Chemical compound COC(=O)C1=CC=CN=C1C(=O)OC YLGIBCYHQZTFQL-UHFFFAOYSA-N 0.000 description 1
- UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 150000002668 lysine derivatives Chemical class 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- RHVNHKWMQOUSLJ-UHFFFAOYSA-N methoxymethanamine;hydrochloride Chemical compound Cl.COCN RHVNHKWMQOUSLJ-UHFFFAOYSA-N 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 238000012829 orthopaedic surgery Methods 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical class [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- PNGLEYLFMHGIQO-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methoxyanilino)-2-hydroxypropane-1-sulfonate;dihydrate Chemical compound O.O.[Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(OC)=C1 PNGLEYLFMHGIQO-UHFFFAOYSA-M 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- WXGGVOBNOVOVAM-UHFFFAOYSA-N tert-butyl 2-(2-methylpropyl)piperazine-1-carboxylate Chemical compound CC(C)CC1CNCCN1C(=O)OC(C)(C)C WXGGVOBNOVOVAM-UHFFFAOYSA-N 0.000 description 1
- YJVXSJIDRHBQMJ-UHFFFAOYSA-N tert-butyl 3,4-dihydropyridine-2-carboxylate Chemical compound C(C)(C)(C)OC(=O)C=1CCC=CN1 YJVXSJIDRHBQMJ-UHFFFAOYSA-N 0.000 description 1
- TUHLLLOEMLVICN-UHFFFAOYSA-N tert-butyl 8-acetyloxy-2-chloro-7,8-dihydro-5h-1,6-naphthyridine-6-carboxylate Chemical compound C1=C(Cl)N=C2C(OC(=O)C)CN(C(=O)OC(C)(C)C)CC2=C1 TUHLLLOEMLVICN-UHFFFAOYSA-N 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- PBIMIGNDTBRRPI-UHFFFAOYSA-N trifluoro borate Chemical compound FOB(OF)OF PBIMIGNDTBRRPI-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Definitions
- the invention relates to the field of medicinal chemistry, in particular to a plasmin inhibitor, its preparation method and its application in the pharmaceutical field.
- Plasmin is a proteolytic enzyme that degrades fibrin.
- the hemostatic mechanism is triggered: vasoconstriction, platelet plug formation, initiation of the coagulation process, and eventual formation of stable fibrin.
- the fibrinolytic system is activated, which maintains a balance between the formation and cleavage of fibrin, and plays a role in maintaining vascular patency and remodeling the damaged blood vessel wall in the process of repairing damaged blood vessel walls. damage tissue (Tengborn L, M, Berntorp E. Thromb Res. 2015 Feb;135(2):231-42).
- the fibrinolytic system includes plasminogen, tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA).
- Plasminogen binds to lysine residues on the surface of fibrin and is converted to plasmin by an activator (ie, tPA) released from endothelial cells.
- Fibrinolysis inhibition can be used to treat bleeding.
- Antifibrinolytic use can reduce blood loss in cardiac surgery, trauma, orthopaedic surgery, solid organ transplantation, obstetrics and gynecology, neurosurgery and non-surgical diseases (Ng W, Jerath A, M. Anaesthesiol Intensive Ther.
- Tranexamic acid is a synthetic lysine derivative and antifibrinolytic agent that forms a reversible complex with plasminogen. By combining with plasminogen, it blocks the interaction of plasminogen and plasmin heavy chain with fibrin lysine residues, thereby preventing the combination of plasminogen and fibrin surface, thereby delaying fibrinolysis.
- Tranexamic acid has been approved for the treatment of severe menstrual bleeding and various surgical bleeding disorders, and is currently the most commonly used hemostatic drug in clinical practice. However, a large number of literature reports show that tranexamic acid is prone to gastrointestinal adverse reactions after oral administration, such as nausea, vomiting, diarrhea, and indigestion, and its dosage is large, which may cause complications such as epilepsy in patients.
- aminocaproic acid Other similar hemostatic drugs, such as aminocaproic acid, have problems such as rapid excretion from the human body, weak hemostatic effect, short duration of action and more toxic reactions.
- the mechanism of aminotoluic acid is the same as that of aminocaproic acid, and its effect is 4 to 5 times stronger than that of aminocaproic acid. It has a significant effect on general chronic bleeding, but has no hemostatic effect on trauma bleeding and cancer bleeding. In addition, excessive dosage can also promote thrombosis.
- Aprotinin a hemostatic drug commonly used in heart bypass surgery, was also withdrawn from the market by the FDA in 2008 because it could induce renal failure, myocardial infarction, and heart failure.
- Hemostatic drugs with other mechanisms such as carbachol, which acts on blood vessels, can induce epilepsy with repeated use; thrombin, a hemostatic drug that promotes the coagulation process, can only be used for gastrointestinal bleeding or local bleeding.
- One of the objectives of the present invention is to overcome the above-mentioned defects of the prior art and provide a new compound with coagulation and hemostatic activities.
- the present invention provides the compound represented by the following formula I structure, its pharmaceutically acceptable salts, hydrates, isomers, prodrugs and mixtures:
- R 1 is selected from hydrogen, hydroxyl, amino, alkyl, alkoxy, -NH-alkyl, cycloalkyl, aryl, alicyclic, and aromatic heterocyclic groups; the R 1 can be optionally 1-2 groups selected from hydroxyl, alkyl, arylalkyl, halogen, aryl, cycloalkyl group substitution;
- R2 independently of one another is selected from hydrogen , carboxyl, amido, alkyl, -NH-alkyl, -CH2O - alkyl, -CH2NH - alkyl, -COO-alkyl, -CONH-alkyl , cycloalkyl, aryl, alicyclic heterocyclic, aromatic heterocyclic, arylalkyl, cycloalkylalkyl; the R 2 can optionally be 1-2 selected from hydroxyl, alkyl, alkoxy group substitution of radicals; or two R 2 together with the attached carbon atoms form cycloalkyl, alicyclic heterocyclyl;
- R 3 is selected from hydrogen, halogen, specifically, R 3 is selected from hydrogen, fluorine, chlorine and bromine.
- the present invention provides compounds of the following structure of formula I', pharmaceutically acceptable salts, hydrates, isomers, prodrugs and mixtures thereof:
- R 1 is selected from hydrogen, hydroxyl, amino, alkyl, alkoxy, -NH-alkyl, cycloalkyl, aryl, alicyclic, and aromatic heterocyclic groups; the R 1 can be optionally 1-2 groups selected from hydroxyl, alkyl, halogen, aryl, cycloalkyl are substituted;
- R 2 is selected from hydrogen, carboxyl, amido, alkyl, -NH-alkyl, -CH2O - alkyl, -CH2NH - alkyl, -COO-alkyl, -CONH-alkyl, cycloalkane group, aryl group, alicyclic heterocyclic group, aromatic heterocyclic group; the R 2 can be optionally substituted by 1-2 groups selected from hydroxyl and alkyl;
- R 3 is selected from hydrogen, halogen, specifically, R 3 is selected from hydrogen, fluorine, chlorine and bromine.
- R 1 is selected from hydrogen, hydroxyl, amino, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, -NH-C 1 to C 6 alkyl, C 3 - C 6 cycloalkyl group, 6- to 10-membered aryl group, 4- to 10-membered alicyclic heterocyclic group, 5- to 10-membered aromatic heterocyclic group; the R 1 can optionally be 1-2 selected from hydroxyl, C 1 - C 4 alkyl, halogen, 6-10 membered aryl-C 1 to C 4 alkyl, 6-10 membered aryl or aromatic heterocyclyl, C 3 -C 6 cycloalkyl group substitution.
- R 1 is selected from the group consisting of hydrogen, hydroxy, amino, phenyl, pyridyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, -NH-C 1 to C 6 Alkyl, C 3 -C 6 cycloalkyl, 4- to 7-membered alicyclic heterocyclic group; the R 1 is optionally 1-2 selected from hydroxyl, C 1 -C 4 alkyl, F, Cl, Br , phenyl, benzyl, cyclopropyl group substituted.
- R 1 is selected from the group consisting of hydrogen, hydroxy, amino, phenyl, benzyl, pyridyl, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy group, propoxy, -NHCH 3 , -NHCH 2 CH 3 , -NHCH 2 CH 2 CH 3 , cyclopropyl, cyclobutyl, cyclopentyl, piperidinyl, morpholinyl, piperazinyl, thio morpholinyl, 1-oxide-4-thiomorpholinyl, 1,1-dioxide-4-thiomorpholinyl; the R 1 is optionally 1-2 selected from hydroxyl, F , Cl, Br, methyl, ethyl, propyl, isopropyl, phenyl, benzyl, cyclopropyl group substitution.
- R 1 is selected from hydrogen, C 1 -C 4 alkoxy, morpholinyl, piperazinyl, thiomorpholinyl, 1-oxide-4-thiomorpholinyl and 1,1-dioxide-4-thiomorpholinyl, the R 1 is optionally substituted with 1-2 groups selected from hydroxy and benzyl.
- R 2 is selected from hydrogen, carboxyl, amido, C 1 -C 6 alkyl, -CH 2 OC 1 to C 6 alkyl, -CH 2 NH-C 1 to C 6 alkane base, -COO-C 1 to C 6 alkyl, -CONH-C 1 to C 6 alkyl, C 3 -C 8 cycloalkyl, 6 to 10 membered aryl, 4 to 10 membered alicyclic, 5 to 10-membered aromatic heterocyclic group; the R 2 can be optionally substituted by 1-2 groups selected from hydroxyl, C 1 -C 4 alkyl;
- R 2 is selected from hydrogen, carboxyl, amido, C 1 -C 6 alkyl, -CH 2 OC 1 to C 6 alkyl, -CH 2 NH-C 1 to C 6 alkane base, -COO-C 1 to C 6 alkyl, -CONH-C 1 to C 6 alkyl, C 3 -C 6 cycloalkyl, 6-membered aryl, 4- to 7-membered alicyclic, 6-membered aryl Heterocyclyl; the R 2 is optionally substituted with 1-2 groups selected from hydroxyl, C 1 -C 4 alkyl;
- R 2 is selected from hydrogen, carboxyl, amido, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, pentyl, -CH 2 OCH 3 , -CH2OCH2CH3 , -CH2OCH2CH2CH3 , -CH2NHCH3 , -CH2NHCH2CH3 , -CH2NHCH2CH2CH3 , -COOCH3 , -COOCH2CH _ _ _ _ _ 3 , -COOCH 2 CH 2 CH 3 , -CONHCH 3 , -CONHCH 2 CH 3 , -CONHCH 2 CH 2 CH 3 , , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, benzyl, Pyridyl, piperidinyl, morpholinyl, thi
- R 2 are independently of each other selected from hydrogen, carboxyl, C 1 -C 6 alkyl, -CH 2 OC 1 to C 6 alkyl, -COO-C 1 to C 6 alkyl, C 3 -C 6 cycloalkyl, phenyl-C 1 to C 4 alkyl and C 3 -C 6 cycloalkyl-C 1 to C 4 alkyl, wherein said alkyl, cycloalkyl and phenyl optionally substituted with 1-2 groups selected from hydroxyl and C 1 -C 4 alkoxy; or two R 2 together with the attached carbon atoms form C 3 -C 6 cycloalkyl or tetrahydropyridine Ran base.
- one of R 2 is hydrogen.
- R3 is selected from hydrogen and fluorine.
- R 1 and R 2 are not both hydrogen
- R 1 , R 2 , R 3 are not simultaneously hydrogen.
- the compounds of formula I described in the present invention have the following structure:
- Another object of the present invention is to provide a pharmaceutical composition
- a pharmaceutical composition comprising at least one of the aforementioned compounds, or pharmaceutically acceptable salts, hydrates, isomers, prodrugs and mixtures thereof, and at least one pharmaceutically acceptable compound Accepted excipients.
- Another object of the present invention is to provide the aforementioned compounds or their pharmaceutically acceptable salts, hydrates, isomers, prodrugs and mixtures, or pharmaceutical compositions for use in preparing medicines.
- the medicine has the therapeutic activities of coagulation and hemostasis, and can be used for abnormal bleeding caused by hyperfibrinolysis, surgical operation and postoperative bleeding.
- Another object of certain inventions is to provide a method of treating and/or alleviating a bleeding disease or disorder comprising administering to a patient in need thereof one or more of the foregoing pharmaceutical compositions or compounds of formula I or pharmaceutically acceptable thereof Accepted salts, hydrates, isomers, prodrugs or mixtures.
- pharmaceutically acceptable means suitable for use in contact with human and animal tissues without undue toxicity, irritation, allergic reactions or other problems or complications, and with reasonable benefit / risk ratio.
- salts refers to salts of the compounds of the present invention, prepared from compounds with specific substituents discovered by the present invention and relatively non-toxic acids or bases.
- base addition salts can be obtained by contacting the neutral forms of such compounds with a sufficient amount of base in neat solution or in a suitable inert solvent.
- acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of acid in neat solution or in a suitable inert solvent.
- the compounds of the present invention may exist in specific geometric or stereoisomeric forms.
- the present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers isomers, (D)-isomers, (L)-isomers, and racemic and other mixtures thereof, all of which are within the scope of the present invention.
- Alkyl refers to a straight-chain or branched-chain saturated aliphatic hydrocarbon group, for example: C 1 -C 4 alkyl and C 1 -C 6 alkyl refer to 1 to 4 carbon atoms and 1 to 6 carbon atoms, respectively Saturated aliphatic hydrocarbon groups of carbon atoms, including but not limited to methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, 3,3-dimethylbutyl, etc. and their various isomers.
- Alkoxy refers to -O-alkyl; for example: C 1 -C 6 alkoxy refers to straight or branched alkoxy containing 1 to 6 carbons, C 1 -C 3 alkoxy The radical refers to a straight-chain alkoxy group or a branched-chain alkoxy group containing 1 to 3 carbons. Typical alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and the like.
- Cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent.
- C 3 -C 6 cycloalkyl refers to a cycloalkyl group containing 3 to 6 carbon atoms
- typical C 3 -C 6 cycloalkyl groups include, but are not limited to: cyclopropyl, cyclobutyl, cyclopentane cyclopentenyl, cyclohexyl, cyclohexenyl, etc.
- Aliphatic heterocyclyl refers to a saturated monocyclic hydrocarbon substituent wherein one or more ring atoms are substituted with heteroatoms selected from N, O, S, the remaining ring atoms are carbon, and wherein the S heteroatom is optionally Oxidized.
- “3-8 membered alicyclic heterocycle” refers to a saturated cyclic hydrocarbon substituent containing 3-8 ring atoms, wherein one or more ring atoms are replaced by heteroatoms selected from N, O, S, and the remaining rings The atoms are carbon, and the S heteroatoms therein are optionally oxidized.
- alicyclic groups in the present invention include, but are not limited to: oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, piperidinyl, piperazinyl, thiomorpholinyl, thiomorpholinyl, 1-oxide-4-thiomorpholinyl and 1,1-dioxide-4-thiomorpholinyl, etc.
- Aromatic heterocyclyl refers to an aromatic cyclic substituent wherein one or more ring atoms are substituted with a heteroatom selected from N, O, S, and the remaining ring atoms are carbon.
- “5-6 membered aromatic heterocyclic group” refers to an aromatic heterocyclic group containing 5 to 6 ring atoms, and specific examples include but are not limited to pyridyl, pyrimidinyl, imidazolyl, pyridazinyl, pyrazole base, thiazolyl, oxazolyl, isoxazolyl, 1,2,4-oxadiazolyl.
- Aryl refers to an aromatic ring group, for example, "6-10 membered aryl” refers to an aromatic ring group containing 6 to 10 carbon ring atoms, and examples of the aryl moiety include phenyl, naphthyl, and the like.
- Halogen includes fluorine, chlorine, bromine and iodine.
- DMF means N,N-dimethylformamide
- THF means tetrahydrofuran
- Me means methyl.
- Step 1 Preparation of tert-butyl 2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate
- Step 2 Preparation of 6-(tert-butoxycarbonyl)-2-chloro-5,6,7,8-tetrahydro-1,6-naphthyridine-1-oxide
- Step 3 Preparation of 8-acetoxy-2-chloro-7,8-dihydro-1,6-naphthopyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 4 Preparation of 2-chloro-8-hydroxy-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 5 Preparation of dimethyl 6-acetyl-2-chloro-5,6-dihydro-1,6-naphthyridine-7,7(8H)-dicarboxylate
- 6-Chloro-2,3-bis(chloromethyl)pyridine (2.10g) was weighed and dissolved in N,N-dimethylformamide (15mL), followed by adding dimethyl acetamidomalonate ( 2.17g) and sodium hydride (0.40g). The reaction was carried out at room temperature for 1 hour, and sodium hydride (0.40 g, ) was added under an ice bath, and the reaction was carried out at room temperature overnight. TLC showed the reaction was complete. Ethyl acetate and water were added, the mixture was separated and extracted, and the organic phase was concentrated to dryness. The obtained crude product was purified by column chromatography to obtain the title compound (1.74 g).
- Step 7 Preparation of methyl 2-chloro-5,6,7,8-tetrahydro-1,6-naphthyridine-7-carboxylate hydrochloride
- Step 8 Preparation of 6-(tert-butyl)7-methyl 2-chloro-7,8-dihydro-1,6-naphthyridine-6,7(5H)-dicarboxylate
- Step 1 Preparation of tert-butyl 2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate
- Step 2 Preparation of tert-butyl 2-cyano-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate
- Step 1 Preparation of tert-butyl 2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate
- Step 2 Preparation of 6-(tert-butoxycarbonyl)-2-chloro-5,6,7,8-tetrahydro-1,6-naphthyridine-1-oxide
- Step 3 Preparation of 8-acetoxy-2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 4 Preparation of 8-acetoxy-2-cyano-7,8-dihydro-1,6-naphthyridine-6-(5H)-carboxylic acid tert-butyl ester
- Step 5 Preparation of 8-hydroxy-2-(imino(methoxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 1 Preparation of 2-chloro-8-((methylsulfonyl)oxy)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 2 Preparation of 8-azido-2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 3 Preparation of 8-amino-2-chloro-7,8-dihydro-1,6-naphthopyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 4 Preparation of 8-((tert-butoxycarbonyl)amino)-2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 5 Preparation of 8-((tert-butoxycarbonyl)amino)-2-cyano-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 6 Preparation of 8-amino-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylate hydrochloride
- Step 1 Preparation of 2-chloro-8-((2-hydroxyethyl)amino)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 2 tert-butyl 8-((tert-butoxycarbonyl)(2-hydroxyethyl)amino)-2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate preparation
- Step 3 8-((tert-Butoxycarbonyl)(2-hydroxyethyl)amino)-2-cyano-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester preparation
- Step 4 Preparation of 8-((2-hydroxyethyl)amino)-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylic acid dihydrochloride
- Step 1 Preparation of 2-chloro-8-((methylsulfonyl)oxy)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 2 Preparation of 2-chloro-8-morpholino-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 3 Preparation of 2-cyano-8-morpholino-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 4 Preparation of 8-morpholino-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylate hydrochloride
- Step 1 Preparation of 2-chloro-8-(1,1-dioxothiomorpholino)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 2 Preparation of 2-cyano-8-(1,1-dioxothiomorpholino)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 3 Preparation of 8-(1,1-Dioxothiomorpholino)-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylate hydrochloride
- Step 1 Preparation of 2-chloro-7-(hydroxymethyl)-7,8-dihydro-1,6-naphthyridine-6-(5H)-carboxylic acid tert-butyl ester
- Step 2 7-((3-((tert-butyldimethylsilyl)oxy)propoxy)methyl)-2-chloro-7,8-dihydro-1,6-naphthyridine- Preparation of 6(5H)-tert-butyl formate
- Step 3 6-(tert-Butyl)2-methyl 7-((3-((tert-butyldimethylsilyl)oxy)propoxy)methyl)-7,8-dihydro-1
- Step 4 6-(tert-Butoxycarbonyl)-7-((3-((tert-butyldimethylsilyl)oxy)propoxy)methyl)-5,6,7,8- Preparation of tetrahydro-1,6-naphthyridine-2-carboxylic acid
- Step 5 Preparation of 7-((3-hydroxypropoxy)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylate hydrochloride
- 6-(tert-butoxycarbonyl)-7-((3-((tert-butyldimethylsilyl)oxy)propoxy)methyl)-5,6 prepared in step 4 was ,7,8-Tetrahydro-1,6-naphthyridine-2-carboxylic acid crude product was added to 1,4-dioxane solution of hydrochloric acid (4M, 2mL), stirred for 30 minutes, LCMS detected the reaction was complete, concentrated under reduced pressure , purified by pre-HPLC to give the title compound (28.3 mg).
- Step 1 Preparation of 7-carbamoyl-2-chloro-7,8-dihydro-1,6-naphthyridine-6-(5H)-carboxylic acid tert-butyl ester
- 6-(tert-butoxycarbonyl)-2-chloro-5,6,7,8-tetrahydro-1,6-naphthyridine-7-carboxylic acid (86 mg) was dissolved in N,N-dimethyl In formamide (4 mL), under an ice bath, 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (157mg), chlorine Ammonium chloride (87 mg) and N,N-diisopropylethylamine (356 mg) were added, stirred at room temperature overnight, and the reaction was complete as detected by LCMS.
- Step 2 Preparation of 6-(tert-butyl) 2-methyl 7-carbamoyl-7,8-dihydro-1,6-naphthyridine-2,6(5H)-dicarboxylate
- Step 3 Preparation of 6-(tert-butoxycarbonyl)-7-carbamoyl-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylic acid
- Step 4 Preparation of 7-carbamoyl-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylate hydrochloride
- Step 1 Preparation of 2-chloro-7-(1-hydroxycyclopropyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 2 6-(tert-Butyl)2-methyl 7-(1-hydroxycyclopropyl)-7,8-dihydro-1,6-naphthyridine-2,6(5H)-dicarboxylate preparation
- Step 3 Preparation of 7-(1-hydroxycyclopropyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylate hydrochloride
- the reaction system was placed in an ice bath, quenched by dropwise addition of water, extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
- the obtained crude product was purified by silica gel column chromatography to obtain the title compound (38 mg) .
- Step 3 6-(tert-Butyl)2-methyl-7-(4-((tert-butyldimethylsilyl)oxy)but-1-en-1-yl)-7,8- Preparation of dihydro-1,6-naphthyridine-2,6(5H)-dicarboxylate
- Step 4 6-(tert-Butyl)2-methyl 7-(4-((tert-butyldimethylsilyl)oxy)butyl)-7,8-dihydro-1,6-naphthalene Preparation of pyridine-2,6(5H)-dicarboxylate
- Step 6 Preparation of 7-(4-hydroxybutyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylate hydrochloride
- Step 1 Preparation of 2-chloro-7-(((3-hydroxypropyl)amino)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 2 7-(((tert-butoxycarbonyl)(3-hydroxypropyl)amino)methyl)-2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)- Preparation of tert-butyl formate
- the tertiary 2-chloro-7-(((3-hydroxypropyl)amino)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid obtained in step 1 was The butyl ester was dissolved in methanol (5 mL), and di-tert-butyl dicarbonate (87 mg) was added and stirred for 1 hour. The reaction was completed by LCMS. Concentrate under reduced pressure. The obtained crude product was purified by silica gel column chromatography to obtain the title compound (67 mg).
- Step 3 6-(tert-Butyl)2-methyl 7-(((tert-butoxycarbonyl)(3-hydroxypropyl)amino)methyl)-7,8-dihydro-1,6-naphthalene Preparation of pyridine-2,6(5H)-dicarboxylate
- Step 4 Preparation of methyl 7-(((3-hydroxypropyl)amino)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylate
- Step 5 Preparation of 7-(((3-hydroxypropyl)amino)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylate hydrochloride
- Step 1 Preparation of 2-chloro-7-(hydroxy(phenyl)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 3 Preparation of methyl 7-(hydroxy(phenyl)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylate
- Step 4 Preparation of 7-(Hydroxy(phenyl)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylate hydrochloride
- Step 1 Preparation of 6-(tert-butoxycarbonyl)-2-chloro-5,6,7,8-tetrahydro-1,6-naphthyridine-7-carboxylic acid
- Step 2 Preparation of 2-chloro-7-(methoxy(methyl)carbamoyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- 6-(tert-Butoxycarbonyl)-2-chloro-5,6,7,8-tetrahydro-1,6-naphthyridine-7-carboxylic acid (0.95 g) was dissolved in dichloromethane (20 mL) at room temperature , N,N-diisopropylethylamine (3.0 mL), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphoric acid were added in turn The salt (1.28 g), methoxymethylamine hydrochloride (0.6 g) was stirred overnight, TLC showed the reaction was complete.
- Step 3 Preparation of 2-chloro-7-formyl-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- the reaction system was placed in an ice bath, water was added dropwise to quench for 10 minutes, saturated sodium potassium tartrate solution (20 mL) was added, stirred for 20 minutes, extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
- the obtained crude product was purified by silica gel column chromatography to obtain the title compound (0.54 g).
- Step 4 7-(4-((tert-butyldimethylsilyl)oxy)-1-hydroxybutyl)-2-chloro-7,8-dihydro-1,6-naphthyridine-6 Preparation of (5H)-tert-butyl formate
- the reaction system was placed in an ice bath, quenched by dropwise addition of water for 10 minutes, extracted with ethyl acetate three times, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
- the obtained crude product was purified by silica gel column chromatography to obtain the title Compound (70 mg).
- Step 5 6-(tert-Butyl)2-methyl 7-(4-(((tert-butyldimethylsilyl)oxy)-1-hydroxybutyl)-7,8-dihydro- Preparation of 1,6-naphthyridine-2,6(5H)-dicarboxylate
- Step 6 Preparation of methyl 7-(1,4-dihydroxybutyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylate
- Step 7 Preparation of 7-(1,4-dihydroxybutyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylate hydrochloride
- Step 1 8-(4-(tert-Butoxycarbonyl)-3-isobutylpiperazin-1-yl)-2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H Preparation of )-tert-butyl formate
- Step 2 8-(4-(tert-Butoxycarbonyl)-3-isobutylpiperazin-1-yl)-2-cyano-7,8-dihydro-1,6-naphthyridine-6( Preparation of 5H)-tert-butyl formate
- Step 3 Preparation of 8-((3-isobutylpiperazin-1-yl)-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylate hydrochloride
- Step 1 Preparation of 8-(2-benzylmorpholino)-2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 2 Preparation of 8-(2-benzylmorpholino)-2-cyano-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 3 Preparation of 8-(2-benzylmorpholino)-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylate hydrochloride
- Step 1 Preparation of 6-(tert-butyl) 2,7-dimethyl 7,8-dihydro-1,6-naphthyridine-2,6,7(5H)-tricarboxylate
- Step 2 Preparation of 6-(tert-butoxycarbonyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-2,7-dicarboxylic acid
- Step 3 Preparation of 6-benzyl-3-fluoro-2-((4-methoxybenzyl)oxy)-7,8-dihydro-1,6-naphthyridin-5(6H)-one
- Step 4 Preparation of 6-benzyl-3-fluoro-2-((4-methoxybenzyl)oxy)-5,6,7,8-tetrahydro-1,6-naphthyridine
- Step 5 Preparation of 6-benzyl-2-chloro-3-fluoro-5,6,7,8-tetrahydro-1,6-naphthyridine
- Step 7 Preparation of 6-(tert-butoxycarbonyl)-2-chloro-3-fluoro-5,6,7,8-tetrahydro-1,6-naphthyridine
- Step 8 Preparation of 6-(tert-butyl)2-methyl 3-fluoro-5,6,7,8-tetrahydro-1,6-naphthyridine-2,6-dicarboxylate
- Step 9 Preparation of 6-(tert-butoxycarbonyl)-3-fluoro-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylic acid
- Step 10 Preparation of 3-fluoro-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylate hydrochloride
- Pentan-3-one (10.73 g) was weighed and dissolved in tetrahydrofuran (300 mL), tetraethyl titanate (46 g) and 2-methylpropane-2-sulfinamide (12 g) were added, and nitrogen was replaced with 3 The second time, the reaction was heated at 65 °C for 20 hours.
- LC-MS monitored the completion of the reaction, water (30 mL) was added to the system, a large amount of solid was precipitated, suction filtered, the organic phase was dried, concentrated to dryness, and purified by column chromatography to obtain the title compound (10.8 g).
- Step 2 Preparation of N-(3-((3-bromo-6-methoxypyridin-2-yl)methyl)pent-3-yl)-2-methylpropane-2-sulfinamide
- reaction was monitored by LC-MS, quenched by adding saturated ammonium chloride solution, extracted with ethyl acetate three times, the organic phase was dried, concentrated to dryness, and purified by column chromatography to obtain the title compound (11.3 g).
- Step 3 Preparation of 2-(2-((tert-butylsulfinyl)amino)-2-ethylbutyl)-6-methoxynicotinic acid ethyl ester
- Step 4 Preparation of 7,7-diethyl-2-methoxy-7,8-dihydro-1,6-naphthyridin-5(6H)-one
- Step 5 Preparation of 7,7-diethyl-2-methoxy-5,6,7,8-tetrahydro-1,6-naphthyridine
- Step 6 Preparation of 7,7-diethyl-5,6,7,8-tetrahydro-1,6-naphthyridin-2-ol
- Step 7 Preparation of 2-chloro-7,7-diethyl-5,6,7,8-tetrahydro-1,6-naphthyridine
- Step 8 Preparation of 2-chloro-7,7-diethyl-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 9 Preparation of 6-(tert-butyl)2-ethyl 7,7-diethyl-7,8-dihydro-1,6-naphthyridine-2,6(5H)-dicarboxylate
- Step 10 Preparation of 6-(tert-butoxycarbonyl)-7,7-diethyl-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylic acid
- Step 11 Preparation of 7,7-diethyl-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carboxylate hydrochloride
- Inhibition rate % (1- Clot lysis time of negative control well/ Clot lysis time of compound well) ⁇ 100%
- the inhibitory effect of the compounds of the present invention on plasma clot degradation was determined by the above tests, and the IC 50 values of the compounds of the present invention were calculated to be significantly lower than those of tranexamic acid, a hemostatic drug commonly used in clinical practice, such as the compound of Example 1 of the present invention.
- the inhibition IC50 of plasma clot degradation is only 1/4 of that of tranexamic acid.
- Test data show that the compounds of the present invention can effectively inhibit the degradation of plasma clots, have excellent coagulation and hemostatic activities, and their effective doses are far lower than the most frequently used hemostatic drugs in clinical practice, and can effectively avoid high-dose medication belts. Adverse reactions and complications from coming, have an excellent drug prospects.
- Test example 2 monkey PK experimental data
- the compound was weighed and dissolved in physiological saline to prepare a 0.5 mg/mL clear intravenous administration solution.
- the drugs were administered according to the following schedule. At each time point after administration, about 1 mL of blood was collected from the forelimb vein and placed in a heparin sodium anticoagulation tube. Blood samples were placed on ice after collection, and centrifuged within 1 hour to separate plasma (centrifugation conditions: 2200 g, 10 minutes, 2-8°C). Plasma samples were stored in a -80°C freezer prior to analysis.
- Mobile phase A 0.1% formic acid in water.
- Mobile phase B 0.1% formic acid in acetonitrile.
- MS detection conditions electrospray ionization (ESI), positive mode, MRM scan.
- Pharmacokinetic parameters were calculated using Phoenix WinNonlin 7.0 through the plasma concentration data at different time points.
- the compounds of the present invention were determined by the above experiments, and the measured pharmacokinetic parameters of cynomolgus monkeys are shown in the following table.
- the compound of the present invention has the advantages of good hemostatic activity, small effective dose, long drug effect time, etc., can avoid various adverse reactions that may occur in clinical high-dose administration, and improve the safety and effectiveness of patient medication.
- the compound of the present invention is convenient to prepare, convenient for industrialized large-scale production, and can effectively reduce the cost of medication.
- the compound of the present invention has good distribution, metabolism and excretion characteristics, and the possibility of drug-drug interaction is low, and can meet the requirements of the pharmacokinetic parameters required to achieve therapeutic effect in the human body.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
时间(min) | 流动相A(%) | 流动相B(%) |
0 | 98 | 2 |
0.60 | 12 | 88 |
1.10 | 12 | 88 |
1.11 | 98 | 2 |
1.40 | 98 | 2 |
实施例 | Cmax(ng/mL) | AUC(h*ng/mL) | CL(mL/h/kg) |
1 | 10573.5 | 4108.2 | 240 |
Claims (18)
- 根据权利要求1或2所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,其特征在于:所述R 1选自氢、羟基、氨基、C 1-C 6烷基、C 1-C 6烷氧基、-NH-C 1至C 6烷基、C 3-C 6环烷基、6至10元芳基、4至10元脂杂环基、5至10元芳杂环基;所述R 1可选择地被1-2个选自羟基、C 1-C 4烷基、卤素、6-10元芳基或芳杂环基、C 3-C 6环烷基的基团取代。
- 根据权利要求1或2所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,其特征在于:所述R 1选自氢、羟基、氨基、苯基、吡啶基、C 1-C 6烷基、C 1-C 6烷氧基、-NH-C 1至C 6烷基、C 3-C 6环烷基、4至7元脂杂环基;所述R 1可选择地被1-2个选自羟基、C 1-C 4烷基、F、Cl、Br、苯基、苄基、环丙基团取代。
- 根据权利要求3所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,其特征在于:所述R 1选自氢、羟基、氨基、苯基、苄基、吡啶基、甲基、乙基、丙基、异丙基、丁基、甲氧基、乙氧基、丙氧基、-NHCH 3、-NHCH 2CH 3、-NHCH 2CH 2CH 3、环丙基、环丁基、环戊基、哌啶基、吗啉基、哌嗪基、硫代吗啉基,1-氧化物-4-硫代吗啉基,1,1-二氧化物-4-硫代吗啉基;所述R 1可选择地被1-2个选自羟基、F、Cl、Br、甲基、乙基、丙基、异丙基、苯基、苄基、环丙基的基团取代。
- 根据权利要求1或2所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,其特征在于:所述R 1选自氢、C 1-C 4烷氧基、吗啉基、哌嗪基、硫代吗啉基、1-氧化物-4-硫代吗啉基和1,1-二氧化物-4-硫代吗啉基,所述R 1可选择地被1-2个选自羟基和苄基的基团取代。
- 根据权利要求1-6中任一项所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,其特征在于:所述R 2选自氢、羧基、酰胺基、C 1-C 6烷基、-CH 2O-C 1至C 6烷基、-CH 2NH-C 1至C 6烷基、-COO-C 1至C 6烷基、-CONH-C 1至C 6烷基、C 3-C 8环烷基、6至10元芳基、4至10元脂杂环基、5至10元芳杂环基;所述R 2可选择地被1-2个选自羟基、C 1-C 4烷基的基团取代。
- 根据权利要求7所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,其特征在于:所述R 2选自氢、、羧基、酰胺基、C 1-C 6烷基、-CH 2O-C 1至C 6烷基、-CH 2NH-C 1至C 6烷基、-COO-C 1至C 6烷基、-CONH-C 1至C 6烷基、C 3-C 6环烷基、6元芳基、4至7元脂杂环基、6元芳杂环基;所述R 2可选择地被1-2个选自、C 1-C 4烷基的基团取代;
- 根据权利要求8所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,其特征在于:所述R 2选自氢、羧基、酰胺基、甲基、乙基、丙基、异丙基、正丁基、叔丁基、 戊基、-CH 2OCH 3、-CH 2OCH 2CH 3、-CH 2OCH 2CH 2CH 3、-CH 2NHCH 3、-CH 2NHCH 2CH 3、-CH 2NHCH 2CH 2CH 3、-COOCH 3、-COOCH 2CH 3、-COOCH 2CH 2CH 3、-CONHCH 3、-CONHCH 2CH 3、-CONHCH 2CH 2CH 3、、环丙基、环丁基、环戊基、环己基、苯基、苄基、吡啶基、哌啶基、吗啉基、硫代吗啉基、1-氧化物-硫代吗啉基、1,1-二氧化物-4-硫代吗啉基;所述R 2可选自的被1-2个选自羟基、甲基、乙基、丙基、异丙基的基团取代。
- 根据权利要求1-6中任一项所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,其特征在于:所述R 2彼此独立地选自氢、羧基、C 1-C 6烷基、-CH 2O-C 1至C 6烷基、-COO-C 1至C 6烷基、C 3-C 6环烷基、苯基-C 1至C 4烷基和C 3-C 6环烷基-C 1至C 4烷基,其中所述的烷基、环烷基和苯基可选择地被1-2个选自羟基和C 1-C 4烷氧基的基团取代;或者两个R 2与所连接的碳原子一起形成C 3-C 6环烷基或四氢吡喃基。
- 根据权利要求1-10中任一项所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,其特征在于:所述R 3选自氢、氟、氯、溴。
- 根据权利要求1-11中任一项所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,其特征在于:所述R 1和R 2不同时为氢。
- 根据权利要求1-11中任一项所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,其特征在于:所述R 1、R 2、R 3不同时为氢。
- 一种药物组合物,包含至少一种权利要1-14中任一项所述的化合物,或其药学上可接受的盐、水合物、异构体、前药及混合物,和至少一种药学上可接受的辅料。
- 权利要求1-14中任一项所述化合物或其药学上可接受的盐、水合物、异构体、前药及混合物、或权利要求15所述的药物组合物,用于制备药物的用途。
- 根据权利要求16所述的用途,其特征在于所述药物具有凝血、止血的治疗活性,可用于纤溶亢进所致异常出血,外科手术和术后出血。
- 一种治疗和/或缓解出血疾病或病症的方法,包括给予所需要的患者一种或多种权利要求1-14中任一项所述的式Ⅰ化合物或其药学上可接受的盐、水合物、异构体、前药或混合物或权利要求15所述的药物组合物。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/264,310 US20240124443A1 (en) | 2021-02-05 | 2022-01-28 | Plasmin inhibitor, preparation method therefor, and application thereof |
KR1020237029324A KR20230142746A (ko) | 2021-02-05 | 2022-01-28 | 플라스민 억제제, 이의 제조 방법 및 이의 용도 |
CA3210694A CA3210694A1 (en) | 2021-02-05 | 2022-01-28 | Plasmin inhibitor, preparation method therefor, and application thereof |
EP22749124.8A EP4289850A1 (en) | 2021-02-05 | 2022-01-28 | Plasmin inhibitor, preparation method therefor, and application thereof |
CN202280013274.7A CN116848122A (zh) | 2021-02-05 | 2022-01-28 | 一种纤溶酶抑制剂、其制备方法及应用 |
JP2023547521A JP2024508390A (ja) | 2021-02-05 | 2022-01-28 | プラスミン阻害剤、その製造方法およびその適用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110163960 | 2021-02-05 | ||
CN202110163960.X | 2021-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022166845A1 true WO2022166845A1 (zh) | 2022-08-11 |
Family
ID=82740846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/074754 WO2022166845A1 (zh) | 2021-02-05 | 2022-01-28 | 一种纤溶酶抑制剂、其制备方法及应用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20240124443A1 (zh) |
EP (1) | EP4289850A1 (zh) |
JP (1) | JP2024508390A (zh) |
KR (1) | KR20230142746A (zh) |
CN (1) | CN116848122A (zh) |
CA (1) | CA3210694A1 (zh) |
TW (1) | TWI803177B (zh) |
WO (1) | WO2022166845A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024109462A1 (zh) * | 2022-11-22 | 2024-05-30 | 西安新通药物研究股份有限公司 | 新型双环类pd-l1抑制剂及其制备方法与医药用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008149163A2 (en) * | 2007-06-06 | 2008-12-11 | Lectus Therapeutics Limited | Potassium ion channel modulators and uses thereof |
WO2012047156A1 (en) * | 2010-10-04 | 2012-04-12 | Astrazeneca Ab | Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases |
CN102459246A (zh) * | 2009-04-07 | 2012-05-16 | 阿斯利康(瑞典)有限公司 | 作为治疗剂的异噁唑-3(2h)-酮类似物 |
WO2015067549A1 (en) * | 2013-11-05 | 2015-05-14 | Bayer Pharma Aktiengesellschaft | (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones as inhibitors of fibrinolysis |
CN107108638A (zh) * | 2014-11-03 | 2017-08-29 | 拜耳制药股份公司 | 哌啶基吡唑并嘧啶酮及其用途 |
-
2022
- 2022-01-28 WO PCT/CN2022/074754 patent/WO2022166845A1/zh active Application Filing
- 2022-01-28 EP EP22749124.8A patent/EP4289850A1/en active Pending
- 2022-01-28 KR KR1020237029324A patent/KR20230142746A/ko unknown
- 2022-01-28 US US18/264,310 patent/US20240124443A1/en active Pending
- 2022-01-28 TW TW111104079A patent/TWI803177B/zh active
- 2022-01-28 CN CN202280013274.7A patent/CN116848122A/zh active Pending
- 2022-01-28 CA CA3210694A patent/CA3210694A1/en active Pending
- 2022-01-28 JP JP2023547521A patent/JP2024508390A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008149163A2 (en) * | 2007-06-06 | 2008-12-11 | Lectus Therapeutics Limited | Potassium ion channel modulators and uses thereof |
CN102459246A (zh) * | 2009-04-07 | 2012-05-16 | 阿斯利康(瑞典)有限公司 | 作为治疗剂的异噁唑-3(2h)-酮类似物 |
WO2012047156A1 (en) * | 2010-10-04 | 2012-04-12 | Astrazeneca Ab | Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases |
WO2015067549A1 (en) * | 2013-11-05 | 2015-05-14 | Bayer Pharma Aktiengesellschaft | (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones as inhibitors of fibrinolysis |
CN107108638A (zh) * | 2014-11-03 | 2017-08-29 | 拜耳制药股份公司 | 哌啶基吡唑并嘧啶酮及其用途 |
Non-Patent Citations (2)
Title |
---|
NG WJERATH AWQSOWICZ M, ANAESTHESIOL INTENSIVE THER, vol. 47, no. 4, 2015, pages 339 - 50 |
TENGBORN LBLOMBACK MBERNTORP E, THROMB RES, vol. 135, no. 2, February 2015 (2015-02-01), pages 231 - 42 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024109462A1 (zh) * | 2022-11-22 | 2024-05-30 | 西安新通药物研究股份有限公司 | 新型双环类pd-l1抑制剂及其制备方法与医药用途 |
Also Published As
Publication number | Publication date |
---|---|
CN116848122A (zh) | 2023-10-03 |
KR20230142746A (ko) | 2023-10-11 |
EP4289850A1 (en) | 2023-12-13 |
US20240124443A1 (en) | 2024-04-18 |
CA3210694A1 (en) | 2022-08-11 |
TWI803177B (zh) | 2023-05-21 |
JP2024508390A (ja) | 2024-02-27 |
TW202237605A (zh) | 2022-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2633248T3 (es) | Derivados de oxopiridina sustituidos y su uso como factor XIa e inhibidores de calicreína plasmática | |
JP2023508482A (ja) | スピロ環含有キナゾリン化合物 | |
ES2659045T3 (es) | Derivados de oxopiridina sustituidos | |
US20150368205A1 (en) | Poly (adp-ribose) polymerase inhibitor | |
KR102494647B1 (ko) | 비시클릭 헤테로아릴 치환된 화합물 | |
EP3702357B1 (en) | Dihydroindolizinone derivative | |
JP2010520293A (ja) | 複素環式部分を含有するメタロプロテアーゼ阻害剤 | |
CA2939326A1 (en) | Condensed 5-oxazolidinone derivative | |
EP3617195A1 (en) | Novel tetrahydronaphthyl urea derivatives | |
TWI803177B (zh) | 一種纖維蛋白溶酶抑制劑、其製備方法及應用 | |
TW202313046A (zh) | 用於癌症治療之組合療法 | |
JP7196931B2 (ja) | (3s)-3-[2-(6-アミノ-2-フルオロピリジン-3-イル)-4-フルオロ-1h-イミダゾール-5-イル]-7-[5-クロロ-2-(1h-テトラゾール-1-イル)フェニル]-2,3-ジヒドロインドリジン-5(1h)-オンの新規結晶 | |
WO2016034137A1 (zh) | 吡唑并[3,4-c]吡啶类衍生物 | |
TWI810773B (zh) | 一種纖溶酶抑制劑、其製備方法及應用 | |
WO2020059812A1 (ja) | 4-({(4s)-1-(4-カルバムイミドイルベンゾイル)-4-[4-(メチルスルホニル)ピペラジン-1-イル]-l-プロリル}アミノ)安息香酸の新規塩およびその新規結晶形 | |
CN100491378C (zh) | 新的取代四环咪唑衍生物,其制备方法,包含它们的药物组合物及它们作为药物的用途 | |
CN114853814A (zh) | 一种纤溶酶抑制剂、其制备方法及应用 | |
US20240300986A1 (en) | Plasmin inhibitor, preparation method therefor and application thereof | |
TWI749881B (zh) | 二氧代哌類衍生物、其製備方法及其在醫藥上的應用 | |
WO2024061365A1 (zh) | 嘧啶并环类化合物及其制备方法与用途 | |
WO2023020512A1 (zh) | 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途 | |
WO2023197984A1 (zh) | 稠环化合物、包含其的药物组合物及应用 | |
CN115703776A (zh) | 一种纤溶酶抑制剂、其制备方法及应用 | |
WO2024017358A1 (zh) | 大环化合物及其药物组合物和应用 | |
WO2022052926A1 (zh) | 芳香乙烯类化合物、其制备方法、中间体、药物组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22749124 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280013274.7 Country of ref document: CN Ref document number: 3210694 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023547521 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 20237029324 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022749124 Country of ref document: EP Effective date: 20230905 |